Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $29.04 Analyst target: $47.50 Upside: 63.57%
Surrozen Inc. is a clinical-stage biopharmaceutical company at the forefront of developing innovative therapeutics using its proprietary SIRPa-IgG platform, which is designed to modulate targeted immune responses. The company's promising pipeline includes novel antibody therapeutics aimed at treating serious oncological and autoimmune disorders, addressing critical unmet medical needs. With a strong focus on research and development, coupled with strategic partnerships, Surrozen is well-positioned to deliver transformative therapies, offering significant potential for growth and a meaningful impact within the biopharmaceutical landscape.
See the full interactive analysis & chart →Informational only — not investment advice.